Notes that Kristin Lucas of ClearTrial will present effective strategies for optimizing clinical trial planning, outsourcing and execution. She will review multiple new clinical development strategies, including the Functional Service Provider (FSP) outsourcing model, Electronic Data Capture (EDC), global studies, and preferred provider relationships, and highlight the areas in which clinical professionals should expect to find cost and time savings in a clinical budget and forecast.

Chicago, IL (PRWEB) January 24, 2008 — ClearTrial, a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing, announced today that Kristin Lucas, Director of Account Management for ClearTrial, will share innovative strategies for optimizing clinical trial planning at the Center for Business Intelligence (CBI) Clinical Trial Forecasting and Budgeting Conference. The conference, to be held February 7-8 at the Marriott Philadelphia West in West Conshohocken, Pennsylvania, provides the pharmaceutical and biotechnology industry with the latest tools, technologies and methods for improving clinical trial feasibility, budget accuracy and contract negotiation.

During the conference, Ms. Lucas will present “Achieve Speed and Cost Savings when Using New Clinical Development Strategies” - a topic of ever-increasing importance given the rapid adoption of new clinical development strategies and technologies. She will review multiple new clinical development strategies, including the Functional Service Provider (FSP) outsourcing model, Electronic Data Capture (EDC), global studies, and preferred provider relationships, and highlight the areas in which clinical professionals should expect to find cost and time savings in a clinical budget and forecast. Just as importantly, Ms. Lucas will point to common pitfalls in these new strategies which often lead to hidden increases in clinical trial costs and time. The session will offer real-world examples of how organizations are dramatically compressing both the time and cost of clinical trial planning, forecasting and execution.

Ms. Lucas brings more than 14 years of experience in the pharmaceutical and biotech industry to the conference. Before joining ClearTrial, she led the Financial Administration division for the Clinical Business Management department at ICOS Corporation (an Eli Lilly company), where she worked on the blockbuster drug Cialis. At ICOS, Ms. Lucas was responsible for establishing best practices in the outsourcing, management, drafting and negotiation of site and vendor agreements, as well as the development of a clinical budgeting/modeling application for lifecycle planning, budgeting and in-licensing opportunity assessment. In addition, she led the audit preparedness project, resulting in ICOS achieving SOX compliance in 2006. Prior to ICOS, Ms. Lucas spent seven years with Genentech, where she was responsible for the negotiation, positioning, and pricing strategy for managed care contracts. She has extensive education and training in project management, negotiation, costing of clinical studies, advanced financial modeling, and marketing and business .

About the Center for Business Intelligence
Founded in 1994 in Massachusetts, CBI Research, Inc. is dedicated to developing market-driven, unbiased conferences in pharmaceuticalsbiotech, medical devices, risk and insurance and managed care markets. CBI offers conferences and summits that serve senior executives and government officials by providing a unique platform for highly focused content and presentation. As a delegate, speaker or sponsor, attendees receive timely information on the latest investment , business strategies, domestic and international regulatory issues, operations and applied technologies. CBI events provide concrete, real life examples that attendees can begin to apply at their organizations immediately for significant impact on costs and revenue. For more information visit http://www.cbinet.com/.

About ClearTrial
ClearTrial is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

For more information, contact:

Mike Lange
ClearTrial
+1 630 424 1601 x102

# # #

ClearTrial, LLC
Mike Lange
630-424-1601
E-mail Information

Trackback URL: http://prweb.com/pingpr.php/UHJvZi1NYWduLVNpbmctQ3Jhcy1Mb3ZlLVplcm8=

Authorities say the versions have A031410 or A041410 written on the bottom of the carton or on the blister strip inside.

Initial tests do not suggest they are a risk to health. But patients have been advised to return them to pharmacies.

Patients with concerns are advised to consult their GP or phone Lilly UK, which makes Cialis, on 0800 085 3847.

“Patients who are in possession of this counterfeit drug should return it immediately,” said Professor Kent Woods, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA).

If patients think that they have taken the product and are concerned about any side effects they should consult their doctor Professor Kent Woods, MHRA

“Whilst initial tests show that the product does not pose an immediate risk to patients, the quality of this product cannot be guaranteed.

“If patients think that they have taken the product and are concerned about any side effects they should consult their doctor.”

The counterfeit tablets are understood to have found their way into some pharmacies. are underway to try to find out how this happened.

Patient complaint

Lilly UK discovered the fake drugs after a patient about a crumbling tablet.

The company investigated and found that the tablet was counterfeit. It then contacted the MHRA.

“We want to emphasise that genuine Cialis is not affected by this matter,” it said in a statement.

It is believed to be the first time that fake drugs have found their way into the legitimate supply chain in the UK for 10 years.

“This incident highlights the need for the greatest vigilance and scrutiny, especially when medicines are into the system other than from their original ,” said Dr Richard Barker, director general of the Association of the British Pharmaceutical Industry.

“The best protection against counterfeiting is to ensure that the products bought are those supplied by the authentic manufacturer.

“Only then can the industry feel confident that its products are reaching patients in the same condition as they left the factory, and that patients are receiving medication that they can trust absolutely.”

are receiving medication that they can trust absolutely.”

Authorities say the versions have A031410 or A041410 written on the bottom of the carton or on the blister strip inside.

Initial tests do not suggest they are a risk to health. But patients have been advised to return them to .

Patients with concerns are advised to consult their GP or phone Lilly UK, which makes Cialis, on 0800 085 3847.

“Patients who are in possession of this counterfeit drug should return it immediately,” said Professor Kent Woods, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA).

If patients think that they have taken the product and are concerned about any side effects they should consult their doctor Professor Kent Woods, MHRA

“Whilst initial tests show that the product does not pose an immediate risk to patients, the quality of this product cannot be guaranteed.

“If patients think that they have taken the product and are concerned about any side effects they should consult their doctor.”

The counterfeit tablets are understood to have found their way into some pharmacies. Investigations are underway to try to find out how this happened.

Patient complaint

Lilly UK discovered the fake drugs after a patient complained about a crumbling tablet.

The company investigated and found that the tablet was counterfeit. It then contacted the MHRA.

“We want to emphasise that genuine Cialis is not affected by this matter,” it said in a statement.

It is believed to be the first time that fake drugs have found their way into the legitimate supply chain in the UK for 10 years.

“This incident highlights the need for the greatest vigilance and scrutiny, especially when medicines are introduced into the system other than from their original ,” said Dr Richard Barker, director general of the Association of the British Pharmaceutical Industry.

“The best protection against counterfeiting is to ensure that the products bought are those supplied by the authentic .

“Only then can the industry feel confident that its products are reaching patients in the same condition as they left the factory, and that patients are receiving medication that they can trust absolutely.”

are receiving medication that they can trust absolutely.”

Authorities say the counterfeit versions have A031410 or A041410 written on the bottom of the carton or on the blister strip inside.

Initial tests do not suggest they are a risk to health. But patients have been advised to return them to pharmacies.

Patients with concerns are advised to consult their GP or phone Lilly UK, which makes Cialis, on 0800 085 3847.

“Patients who are in possession of this counterfeit drug should return it immediately,” said Professor Kent Woods, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA).

If patients think that they have taken the product and are concerned about any side effects they should consult their doctor Professor Kent Woods, MHRA

“Whilst initial tests show that the product does not pose an immediate risk to patients, the quality of this product cannot be guaranteed.

“If patients think that they have taken the product and are concerned about any side effects they should consult their doctor.”

The counterfeit tablets are understood to have found their way into some pharmacies. Investigations are underway to try to find out how this happened.

Patient complaint

Lilly UK discovered the fake drugs after a patient complained about a crumbling tablet.

The company and found that the tablet was counterfeit. It then contacted the MHRA.

“We want to emphasise that genuine Cialis is not affected by this matter,” it said in a statement.

It is believed to be the first time that fake drugs have found their way into the legitimate supply chain in the UK for 10 years.

“This incident highlights the need for the greatest vigilance and scrutiny, especially when medicines are introduced into the system other than from their original ,” said Dr Richard Barker, director general of the of the British Pharmaceutical Industry.

“The best protection against counterfeiting is to ensure that the products bought are those supplied by the authentic manufacturer.

“Only then can the industry feel confident that its products are reaching patients in the same condition as they left the factory, and that patients are receiving medication that they can trust absolutely.”

are receiving medication that they can trust absolutely.”

say the counterfeit versions have A031410 or A041410 written on the bottom of the carton or on the blister strip inside.

Initial tests do not suggest they are a risk to health. But patients have been advised to return them to pharmacies.

Patients with concerns are advised to consult their GP or phone Lilly UK, which makes Cialis, on 0800 085 3847.

“Patients who are in possession of this counterfeit drug should return it immediately,” said Professor Kent Woods, chief executive of the Medicines and Healthcare products Regulatory Agency (MHRA).

If patients think that they have taken the product and are concerned about any side effects they should consult their doctor Professor Kent Woods, MHRA

“Whilst initial tests show that the product does not pose an immediate risk to patients, the quality of this product cannot be guaranteed.

“If patients think that they have taken the product and are concerned about any side effects they should consult their doctor.”

The counterfeit tablets are understood to have found their way into some pharmacies. Investigations are underway to try to find out how this happened.

Patient complaint

Lilly UK discovered the fake drugs after a patient about a crumbling tablet.

The company investigated and found that the tablet was counterfeit. It then contacted the MHRA.

“We want to emphasise that genuine Cialis is not affected by this matter,” it said in a statement.

It is believed to be the first time that fake drugs have found their way into the legitimate supply chain in the UK for 10 years.

“This incident highlights the need for the greatest vigilance and scrutiny, especially when medicines are introduced into the system other than from their original s,” said Dr Richard Barker, director general of the of the British Industry.

“The best protection against counterfeiting is to ensure that the products bought are those supplied by the authentic manufacturer.

“Only then can the industry feel confident that its products are reaching patients in the same condition as they left the factory, and that patients are receiving medication that they can trust absolutely.”

are receiving medication that they can trust absolutely.”